Sanofi has restarted Phase III clinical trials with a potential RNA-interference based hemophilia therapy, fitusiran, and expects to start Phase IIb studies this month with its COVID-19 vaccine candidate developed in collaboration with GlaxoSmithKline plc, but the multinational has halted Phase II studies in Parkinson’s disease of another high-profile product candidate, venglustat.
Phase III studies of fitusiran were put on hold late last year because of side effect concerns including non-fatal thrombotic...








